While cDC2sactivate CD4+ T cells, the cDC1 subset is the most effectivefor CD8+ T cell priming and for driving cell-mediated responsevia the cross presentation of exogenous and endogenous antigens toT cells.17,18 In cancer patients, the presence of cDC1sin the tumor microenvironment was correlated to a better survivaland a higher response to anti-PD1 checkpoint blockade.19,20 Therefore, cDC1s are considered to play a critical role in antitumorimmunity and represent a particularly attractive target for the developmentof cancer vaccines. The gene discussed is CD4; the disease is cancer.